Diabetic Feet Ulcers – Opportunity Examination & Predictions to 2017 – Event-Driven Update: Order report by simply calling marketoptimizer. org in +1 888 391 5441 OR give an email on [email protected] org with Diabetic Foot Ulcers – Opportunity Analysis & Forecasts to 2017 – Event-Driven Update in subject line and your contact details.
Diabetic foot ulcers (DFUs) are a common complications of diabetes, and with the elevating prevalence of diabetes across all markets, the number of people suffering from DFUs is also anticipated to rise. Inspite of the availability of several treatment methods, there are presently few advanced wound care products available to take care of hard-to-heal persistent wounds. In addition , for the past 15 years, Regranex (becaplermin) is the only pharmacologic wound-healing agent available; however , it is seldom used thanks a recognized lack of efficacy.
The DFU market is at this point set to enter an exciting stage with the potential launch of three wound-healing agents within the next five years; Olympus Biotech's trafermin (recombinant human basic fibroblast expansion factor), Macrocure's CureXcell (activated leukocyte suspension), and Derma Sciences' DSC127 (NorLeu3-A[1-7]). The first two topical antibacterials, Innocoll's Cogenzia (gentamicin-collagen sponge) and Dipexium Pharmaceuticals' Locilex (pexiganan acetate cream 1%), are also supposed to launch in the usa and the five major EUROPEAN UNION markets (5EU). Both canal agents provide an alternative way to treat illness by localizing an antibiotic directly with the wound site.
With the creation of these cool product launches, the size of the DFU market is expected to grow considerably during the five-year forecast period.
Complete record available athttp://www.marketoptimizer.org/opportunityanalyzer-diabetic-foot-ulcers-opportunity-analysis-and-forecasts-to-2017-event-driven-update.html.
Key Questions Clarified
The DFU market is designated by the presence of a quantity of unmet needs. What are the...